Design of a large outcome trial for a multivalent human papillomavirus L1 virus-like particle vaccine

Contemporary Clinical Trials
Alain LuxembourgJoshua Chen

Abstract

The 9-valent human papillomavirus (HPV) (9vHPV) vaccine targets the four HPV types (6/11/16/18) covered by the licensed quadrivalent HPV (qHPV) vaccine and five additional types (31/33/45/52/58). A large outcome trial of 9vHPV vaccine was conducted. An active control (qHPV vaccine) was used because a placebo is not ethically acceptable. Since qHPV vaccine is (and 9vHPV vaccine was anticipated to be) highly efficacious against HPV 6/11/16/18, low incidence of HPV 6/11/16/18-associated disease was expected. Consequently, an efficacy comparison of 9vHPV versus qHPV vaccine for HPV 6/11/16/18 would have been prohibitively large in size. Moreover, no minimum antibody level predicting protection against infection or disease is defined for HPV vaccination. As an alternative approach, the two vaccines were compared using immunogenicity bridging for HPV 6/11/16/18 and clinical efficacy for HPV 31/33/45/52/58. The two co-primary objectives were to demonstrate: (1) non-inferior anti-HPV 6/11/16/18 antibody response; and (2) superior efficacy in HPV 31/33/45/52/58-related clinical outcome, for 9vHPV vaccine versus qHPV vaccine. For HPV 6/11/16/18, supportive analyses included a non-inferiority assessment of the percent risk reduction (comp...Continue Reading

References

Sep 5, 2006·Vaccine·D Maxwell Parkin, Freddie Bray
Sep 5, 2006·Vaccine·Anna-Barbara MoscickiLuisa L Villa
Nov 14, 2006·Lancet·Kaye WellingsNathalie Bajos
May 15, 2007·The New England Journal of Medicine·UNKNOWN FUTURE II Study Group
May 15, 2007·The New England Journal of Medicine·Suzanne M GarlandUNKNOWN Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators
Dec 29, 2007·Journal of Lower Genital Tract Disease·L Stewart Massad
Apr 15, 2008·Critical Reviews in Oncology/hematology·H P van de NieuwenhofJ A de Hullu
May 17, 2008·American Journal of Epidemiology·Jill KoshiolJennifer S Smith
Apr 8, 2009·The Lancet Oncology·Véronique BouvardUNKNOWN WHO International Agency for Research on Cancer Monograph Working Group
Jul 30, 2009·BMJ : British Medical Journal·Philip E CastleUNKNOWN Proyecto Epidemiológico Guanacaste (PEG) Group
Oct 19, 2010·The Lancet Oncology·Silvia de SanjoseUNKNOWN Retrospective International Survey and HPV Time Trends Study Group
Dec 5, 2012·Vaccine·David FormanSilvia Franceschi
Dec 5, 2012·Vaccine·John T SchillerSuzanne M Garland
Dec 5, 2012·Vaccine·Lauri E MarkowitzJulia M L Brotherton
Dec 5, 2012·Vaccine·Margaret StanleyConnie Trimble
Jan 1, 2013·Infectious Agents and Cancer·Beatriz SerranoSilvia de Sanjosé
Jul 28, 2013·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Silvia de SanjoséUNKNOWN HPV VVAP study group
Feb 21, 2014·Journal of the National Cancer Institute·Birgitte Baldur-FelskovSusanne K Kjaer
Aug 27, 2014·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·L AlemanyUNKNOWN HPV VVAP study group
Oct 4, 2014·Clinical Trials : Journal of the Society for Clinical Trials·Y H Joshua ChenAlain Luxembourg
Feb 19, 2015·The New England Journal of Medicine·Elmar A JouraUNKNOWN Broad Spectrum HPV Vaccine Study

❮ Previous
Next ❯

Citations

Jan 23, 2016·Contemporary Clinical Trials·Oliver M Bautista, Alain Luxembourg
Sep 15, 2015·Expert Review of Vaccines·Punnee PitisuttithumAlain Luxembourg
Feb 27, 2016·International Journal of Cancer. Journal International Du Cancer·Julia M L BrothertonSilvia Franceschi
Sep 29, 2017·Expert Review of Vaccines·Alain Luxembourg, Erin Moeller
Apr 25, 2019·Human Vaccines & Immunotherapeutics·Li Ping WongGregory D Zimet

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Vaccines

Cancer vaccines are vaccines that either treat existing cancer or prevent development of a cancer.